SWOG clinical trial number
S9702

Detection of Malignant Cells in the Marrow and Peripheral Blood Progenitor Cell Products of Breast Cancer Patients Enrolled on Intergroup Randomized Study S9623

Closed
Phase
Accrual
4%
Abbreviated Title
Detection of malignant cells in marrow and PBPC products
Activated
10/01/1997
Closed
07/15/1999
Participants
NCORP, Members, Medical Oncologists, Pathologists, ECOG, NCCTG, CALGB

Research committees

Breast Cancer

Eligibility Criteria Expand/Collapse

Patients on S9623

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase